Table 2.
Differences between groups with high and low disease impact according to Psoriatic Arthritis Impact of Disease (PsAID) score. Unless otherwise stated, values are presented as median (min-max)*
| Low disease impact, PsAID<4 (n = 41) | High disease impact, PsAID≥4 (n = 119) | p† | |
|---|---|---|---|
| Age, years (mean ± SD) |
47.32 ± 12.14 |
46.20 ± 10.79 |
0.581 |
| Sex, F/M (n) |
27/14 |
94/25 |
0.091 |
| Presence of psoriasis, n (%) |
34 (82.9) |
88 (73.9) |
0.292 |
| Treatment, n (%) |
|
|
0.279 |
| NSAIDs |
4 (9.8) |
11 (9.2) |
>0.999 |
| NSAIDs + csDMARDs |
25 (61.0) |
89(74.8) |
0.110 |
| bDMARDs |
6 (14.6) |
11 (9.2) |
0.380 |
| csDMARDs + bDMARDs |
6 (14.6) |
8 (6.7) |
0.195 |
| Disease duration, years |
2 (0.5-34) |
2 (0.5-23) |
0.741 |
| CRP, mg/L |
1.65 (0.12-11.77) |
6.2 (0.46-82.77) |
<0.001 |
| Erythrocyte sedimentation rate, mm/h |
5 (2-24) |
13 (2-52) |
<0.001 |
| Neutrophil, K/uL (mean ± SD) |
4.51 ± 1.65 |
5.76 ± 1.7 |
<0.001 |
| Lymphocyte, K/uL |
2.30 (1.32-5.15) |
2.12 (0.88-4.48) |
0.066 |
| Platelet, K/uL |
269 (125-446) |
286 (156-533) |
0.134 |
| Albumin, g/dL (mean ± SD) |
4.59 ± 0.22 |
4.41 ± 0.26 |
<0.001 |
| CAR |
0.35 (0.03-1.02) |
1.39 (0.1-19.61) |
<0.001 |
| Neutrophil/lymphocyte ratio |
1.82 (0.73-3.74) |
2.70 (0.85-7.10) |
<0.001 |
| Platelet/lymphocyte ratio |
108.13 (62.52-211.46) |
138.39 (47.47-492.16) |
<0.001 |
| Disease Activity Index for Psoriatic Arthritis | 15.5 (10-28) | 30.32 (11-129) | <0.001 |
*Abbreviations: SD – standard deviation; bDMARDs – biological disease-modifying antirheumatic drugs; CAR – CRP/albumin ratio; CRP – C-reactive protein; csDMARDs – conventional disease-modifying antirheumatic drugs; NSAIDs – non-steroidal anti-inflammatory drugs.
†Numerical variables were evaluated with the independent-samples t test and the Mann-Whitney U test. Categorical data were evaluated with the χ2 test.